Skip to search formSkip to main contentSkip to account menu

ELND005

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

scyllitol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Investigational drugs for treating agitation in persons with dementia
ABSTRACT Introduction: Agitation is common and distressing in persons with dementia, but safe, effective treatments remain… 
2012
2012
Responder Analyses from a 78-Week Phase 2 Placebo-Controlled Study of ELND005 (Scyllo-Inositol) in Mild to Moderate (MM) Alzheimer's Disease (AD) (P04.195)
Objective: To evaluate responder proportions in Mild AD using new responder criteria, to inform selection of optimal definitions… 
2012
2012
Responders to ELND005 (Scyllo-Inositol) Demonstrate Clinical and Biomarker Characteristics Consistent with Mild Alzheimer's Disease (AD): Data from a 78-Week Phase 2 Study in Mild to Moderate (M/M…
Objective: To describe the clinical and biomarker characteristics (v-MRI and CSF) of patients who demonstrated cognitive benefit… 
2011
2011
Population pharmacokinetic analysis of plasma, cerebrospinal fluid and brain ELND005 in patients with mild to moderate Alzheimer's disease
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)